Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01883869 · ClinicalTrials.gov registry record · Phase 1
Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor
A Phase 1 study, sponsored by University of Kentucky.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01883869 is a Phase 1 study that has completed, run by University of Kentucky. The registered enrollment target is 60 participants.
The verdict
NCT01883869, a Phase 1 study, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.
Interventions
- DRUG placebo
- DRUG ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01883869
The ClinicalTrials.gov registry entry for NCT01883869 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kentucky, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01883869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01883869 about?
NCT01883869 is a clinical study titled "Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor". The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.
What is the current status of trial NCT01883869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2013-06. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01883869?
The interventions under investigation include: placebo (DRUG), ticagrelor (DRUG).
Who is sponsoring clinical trial NCT01883869?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.